1. Home
  2. CURV vs SGMT Comparison

CURV vs SGMT Comparison

Compare CURV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

HOLD

Current Price

$1.37

Market Cap

143.3M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.13

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURV
SGMT
Founded
2001
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
143.3M
169.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CURV
SGMT
Price
$1.37
$7.13
Analyst Decision
Hold
Strong Buy
Analyst Count
6
8
Target Price
$1.59
$26.13
AVG Volume (30 Days)
361.1K
2.8M
Earning Date
06-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,092,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$3.32
52 Week High
$5.54
$11.41

Technical Indicators

Market Signals
Indicator
CURV
SGMT
Relative Strength Index (RSI) 37.01 51.92
Support Level $0.96 $7.09
Resistance Level $1.39 $7.20
Average True Range (ATR) 0.12 0.47
MACD -0.02 -0.16
Stochastic Oscillator 31.25 35.13

Price Performance

Historical Comparison
CURV
SGMT

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: